Today: 11 June 2026
Fermi Inc (FRMI) stock jumps nearly 10% as class-action filing adds pressure
6 January 2026
1 min read

Fermi Inc (FRMI) stock jumps nearly 10% as class-action filing adds pressure

New York, January 6, 2026, 12:31 (EST) — Regular session

  • Fermi shares rose about 9.8% in midday trade, after swinging more than $1 intraday.
  • Law firms said a securities-fraud class action has been filed, with a March 6 lead-plaintiff deadline.
  • Investors are watching a Jan. 8–9 conference appearance for fresh detail on tenants and financing.

Fermi Inc (FRMI) shares rose nearly 10% in midday trading on Tuesday, lifting the stock to $9.53 from Monday’s close. The stock ranged from $8.62 to $9.68, with volume topping 5.1 million shares.

The rebound comes as a securities-fraud class action has been filed in the U.S. District Court for the Southern District of New York, Gainey McKenna & Egleston said. The complaint alleges Fermi overstated tenant demand for its Project Matador campus and played down the risks of leaning on a single tenant’s $150 million funding commitment. It also cites a Dec. 12 disclosure that the tenant terminated the arrangement, sending the stock down 33.8% that day, the firm said.

Holzer & Holzer said investors who bought Fermi shares in the October 2025 IPO, or between Oct. 1 and Dec. 11, can ask to be appointed lead plaintiff by March 6. A lead plaintiff is the investor chosen to represent other shareholders and direct the case.

In a separate notice, Glancy Prongay & Murray said Fermi shares have traded as low as $8.59, about 59% below the $21 IPO price. The stock remains far under its offer level even after Tuesday’s bounce.

Fermi raised $682.5 million in its U.S. IPO in late September, selling 32.5 million shares at $21 each, Reuters reported at the time. “There’s no questioning that they’re selling into a lot of demand for AI infrastructure right now,” Renaissance Capital strategist Matt Kennedy said then. Reuters

Fermi, which trades on Nasdaq and in London under FRMI, says it is building a “behind-the-meter” power-and-data campus in Texas designed to deliver up to 11 gigawatts. Behind-the-meter projects link generation directly to a site, rather than sending power into the public grid. investor.fermiamerica.com

Investors have been looking for signs the project can land binding tenant deals and secure financing as the company scales up construction. Any update on tenant commitments, power delivery timing or capital needs can move the stock, given the company’s limited operating history.

Legal claims can take months to play out and can weigh on a stock, especially for companies that may need fresh capital to fund large buildouts. Delays in tenant signings or funding would sharpen the downside if the project timeline slips.

Stock Market Today

  • Johnson Controls International (JCI) Valuation Review Amid Recent Share Decline
    June 11, 2026, 10:52 AM EDT. Johnson Controls International (NYSE:JCI) shares fell 5.7% recently, despite solid annual revenue of US$24.4 billion and net income of US$2 billion. The stock trades slightly above its fair value estimate of US$138.11, which factors in a 9.38% discount rate and modest revenue growth forecast of 5.56%. Analyst models reflect steadier revenue expansion and improved profit margins, yet caution remains due to potential operational disruptions from a new segment structure and execution risks related to cost-saving initiatives. Investors are urged to evaluate both risks and rewards amid the short-term price weakness and maintain a close watch on ongoing financial performance and strategic execution.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Uber stock hit by Melius “Sell” call as robotaxi threat sharpens; Wolfe sets $110 target
Previous Story

Uber stock hit by Melius “Sell” call as robotaxi threat sharpens; Wolfe sets $110 target

Merck stock hits 52-week high as vaccine policy shift and JPM conference loom
Next Story

Merck stock hits 52-week high as vaccine policy shift and JPM conference loom

Go toTop